Estalis® Gynecology A dermal patch containing estradiol/norethindrone acetate used to manage the vasomotor Sx of menopause; vulvar and vaginal atrophy; hypoestrogenism due to hypogonadism, castration, or primary ovarian failure
References in periodicals archive ?
Novogyne manufactures the hormone therapy patches Vivelle-Dot, Vivelle, and CombiPatch.
015 mg/day of levonorgestrel) than CombiPatch, the first estrogen and progestin patch on the U.
The Company's products include Vivelle and Vivelle Dot estrogen transdermal delivery systems, DentiPatch transmucosal patch, and CombiPatch and Estalis estrogen/progestin transdermal delivery systems.
Cost/day is based on the average wholesale price for combiPatch in the 2002 Red Book.
Our study found women using CombiPatch experienced greater improvements in sexual quality of life and lower renin substrate levels, when compared to Prempro users.
rights to market CombiPatch (TM) (estradiol/norethindrone acetate transdermal system) from Aventis Pharmaceuticals, the U.
vi) CombiPatch is a registered trademark of Aventis Pharmaceutical
Combipatch is the only combination estradiol and progestin patch on the market.
RPR announced the training session at their annual National Sales Meeting that concluded today was a rousing success and that their sales force is looking forward to sharing the benefits of CombiPatch with physicians and menopausal women.
CombiPatch is the first transdermal product in the U.
Before CombiPatch, women who would benefit from both estrogen and
3 million, reflecting lower sales of CombiPatch due to the continuing effects of the Women's Health Initiative ("WHI") study and the entry of a new combination patch competitor, as well as the impact of trade customer purchasing patterns on sales of Vivelle(R) family products.